Overview
GlaxoSmithKline (Waste AD) is a 1 MW biomass power plant in the United Kingdom, owned by GlaxoSmithKline. It converts waste into energy, supporting the company's sustainability goals.
GlaxoSmithKline (Waste AD) is a biomass power plant located in the United Kingdom, specifically at coordinates 55.5945, -4.6302. With a capacity of 1 MW, it is a small-scale facility within the biomass power generation sector. The plant is owned by GlaxoSmithKline and is currently operational. The plant utilizes anaerobic digestion (AD) technology to process waste and generate electricity. This technology aligns with the UK's regulatory framework for renewable energy, including the Renewable Obligation and Contracts for Difference schemes. Biomass power plants in the UK are subject to emission standards under the Environmental Permitting Regulations and must comply with sustainability criteria for biomass fuels. As a waste-to-energy facility, GlaxoSmithKline (Waste AD) contributes to reducing landfill waste and generating renewable energy. It supports the company's environmental commitments and the UK's transition to a low-carbon economy. The plant's small capacity means it likely serves local energy needs or provides power for on-site operations.
Environmental context
The plant uses biomass as fuel, which has a lower carbon footprint compared to fossil fuels but still produces CO2 and other emissions. Its small capacity (1 MW) limits its overall environmental impact. Located in the UK, it operates under strict emission regulations, including the Industrial Emissions Directive and UK-specific standards. The plant's waste-to-energy function helps reduce methane emissions from landfills.
Frequently asked questions
GlaxoSmithKline (Waste AD) is located in the United Kingdom at coordinates 55.5945, -4.6302.
It is a biomass power plant that uses anaerobic digestion to convert waste into electricity.
The plant has a capacity of 1 MW, making it a small-scale biomass facility.
Biomass plants in the UK must comply with the Environmental Permitting Regulations, sustainability criteria for biomass fuels, and emission standards under the Industrial Emissions Directive.
The plant is owned by GlaxoSmithKline, a global pharmaceutical company.